*FROM NEWSmax.health
?Anemia increase risk for dementia in elderly
wonder if it is all anemia or Iron deficiency
breakdown would have been more informative.
*Alentuzumab (Anti-CD52) for the treatment of Hypereosinophilic syndrome led to "brisk elimination of symptoms" . Caveat: Alentuzumab side effect. and questionable effect in clearing the bone marrow. Prophylaxis for CMV and Zoster recommended.
"The makers of Alemtuzumab have reportedly withdraw the medication from the united states to prepare for a relaunch in lower dosage" for treatment of refractory Myeloma" (Strati et al...)
Use of GLEEVEC IS DISCUSSEDIN THE ARTICLE
No comments:
Post a Comment